Dr. Xinyong Liu is currently a distinguished principal professor, a designated Ph.D. advisor, Director of the Institute of Medicinal Chemistry, Vice Dean of the School of Pharmaceutical Sciences, Shandong University. He obtained his Ph.D. from Shandong University in 2004. In his medicinal chemistry research fields, he has published more than 300 paper and 6 monographs. In addition, 26 patents have been granted presently.
Dr. Xinyong Liu research work is partly engaged in the rational drug design, synthesis and antiviral evaluation of a variety of molecules that interact with specific enzymes and receptors in viral life cycle (HIV, HBV, HCV, Flu). (1) in anti-HIV drug research, He is focusing on the design and synthesis of novel non-nucleoside HIV-1 reverse transcriptase inhibitors (NNRTIs), and the novel multiple ligands (inhibitors) simultaneously targeting at HIV-1 RT and integrase. (2) in anti-HBV drug research, he is focusing on design and synthesis of some novel non-nucleoside (small molecules) inhibitors. (3) in anti-influenza drug research, he is conducting the neuramidinase inhibitors and RNA polymerase inhibitors. His second ongoing program is design, synthesis and cardiovascular studies of novel factor Xa inhibitors, and synthesis of some natural products from Chinese Traditional Medicine active in cardio/vascular diseases.
